panitumumab
amgen,takeda
['paradigm']
if we are going to recommend treatment paradigms to our patients, we should be able to counsel them on what their quality of life and symptom burden will be like with those paradigms. pros should be in all trials. #asco22 cc 
Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ??????